vs
Side-by-side financial comparison of dLocal Ltd (DLO) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
dLocal Ltd is the larger business by last-quarter revenue ($337.9M vs $177.4M, roughly 1.9× Pacira BioSciences, Inc.). dLocal Ltd runs the higher net margin — 16.5% vs 1.6%, a 14.8% gap on every dollar of revenue. On growth, dLocal Ltd posted the faster year-over-year revenue change (65.2% vs 5.0%).
dLocal Limited is a Uruguayan financial technology company. It provides cross-border payments connecting global merchants to emerging markets.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
DLO vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $337.9M | $177.4M |
| Net Profit | $55.6M | $2.9M |
| Gross Margin | 34.3% | — |
| Operating Margin | 18.6% | 3.9% |
| Net Margin | 16.5% | 1.6% |
| Revenue YoY | 65.2% | 5.0% |
| Net Profit YoY | 87.3% | — |
| EPS (diluted) | $0.18 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $337.9M | $196.9M | ||
| Q3 25 | $282.5M | $179.5M | ||
| Q2 25 | — | $181.1M | ||
| Q1 25 | — | $168.9M | ||
| Q4 24 | $204.5M | $187.3M | ||
| Q3 24 | $185.8M | $168.6M | ||
| Q2 24 | — | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $55.6M | — | ||
| Q3 25 | $141.3M | $5.4M | ||
| Q2 25 | — | $-4.8M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | $29.7M | — | ||
| Q3 24 | $90.8M | $-143.5M | ||
| Q2 24 | — | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 34.3% | 79.5% | ||
| Q3 25 | 36.5% | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | 40.9% | 78.7% | ||
| Q3 24 | 42.1% | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 18.6% | 1.2% | ||
| Q3 25 | 19.7% | 3.5% | ||
| Q2 25 | — | 4.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | 20.7% | 13.2% | ||
| Q3 24 | 22.1% | -82.8% | ||
| Q2 24 | — | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 16.5% | — | ||
| Q3 25 | 50.0% | 3.0% | ||
| Q2 25 | — | -2.7% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | 14.5% | — | ||
| Q3 24 | 48.9% | -85.1% | ||
| Q2 24 | — | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.18 | $0.05 | ||
| Q3 25 | $0.17 | $0.12 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | $0.09 | $0.38 | ||
| Q3 24 | $0.09 | $-3.11 | ||
| Q2 24 | — | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $719.9M | $144.3M |
| Total DebtLower is stronger | $86.7M | — |
| Stockholders' EquityBook value | $569.4M | $653.9M |
| Total Assets | $1.5B | $1.2B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $719.9M | $238.4M | ||
| Q3 25 | $604.5M | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | $425.2M | $484.6M | ||
| Q3 24 | $560.5M | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $86.7M | $372.2M | ||
| Q3 25 | $63.1M | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $39.8M | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $569.4M | $693.1M | ||
| Q3 25 | $504.7M | $727.2M | ||
| Q2 25 | — | $757.8M | ||
| Q1 25 | — | $798.5M | ||
| Q4 24 | $489.0M | $778.3M | ||
| Q3 24 | $457.0M | $749.6M | ||
| Q2 24 | — | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.5B | $1.3B | ||
| Q3 25 | $1.4B | $1.3B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | $1.2B | $1.6B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | 0.54× | ||
| Q3 25 | 0.12× | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 0.08× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $100.4M | — |
| Free Cash FlowOCF − Capex | $99.8M | — |
| FCF MarginFCF / Revenue | 29.5% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 1.80× | — |
| TTM Free Cash FlowTrailing 4 quarters | $378.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $100.4M | $43.7M | ||
| Q3 25 | $315.0M | $60.8M | ||
| Q2 25 | — | $12.0M | ||
| Q1 25 | — | $35.5M | ||
| Q4 24 | $-141.1M | $33.1M | ||
| Q3 24 | $108.3M | $53.9M | ||
| Q2 24 | — | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $99.8M | $43.5M | ||
| Q3 25 | $313.4M | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | $-141.6M | $31.0M | ||
| Q3 24 | $107.1M | $49.8M | ||
| Q2 24 | — | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 29.5% | 22.1% | ||
| Q3 25 | 110.9% | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | -69.2% | 16.6% | ||
| Q3 24 | 57.6% | 29.6% | ||
| Q2 24 | — | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 0.1% | ||
| Q3 25 | 0.6% | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | 0.2% | 1.1% | ||
| Q3 24 | 0.7% | 2.4% | ||
| Q2 24 | — | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.80× | — | ||
| Q3 25 | 2.23× | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | -4.75× | — | ||
| Q3 24 | 1.19× | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DLO
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
